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H3K27M induces defective chromatin spread of
PRC2-mediated repressive H3K27me2/me3 and
is essential for glioma tumorigenesis
Ashot S. Harutyunyan 1, Brian Krug1, Haifen Chen1, Simon Papillon-Cavanagh1, Michele Zeinieh1,
Nicolas De Jay1,2, Shriya Deshmukh1, Carol C.L. Chen1, Jad Belle1, Leonie G. Mikael3, Dylan M. Marchione4,
Rui Li1, Hamid Nikbakht1, Bo Hu1, Gael Cagnone 1, Warren A. Cheung1,5, Abdulshakour Mohammadnia1,
Denise Bechet1, Damien Faury1, Melissa K McConechy1, Manav Pathania6, Siddhant U. Jain7,
Benjamin Ellezam 8, Alexander G. Weil9, Alexandre Montpetit10, Paolo Salomoni11,6, Tomi Pastinen1,5,
Chao Lu 12, Peter W. Lewis 7, Benjamin A. Garcia4, Claudia L. Kleinman1,2, Nada Jabado 1,3 &
Jacek Majewski 1,10

Lys-27-Met mutations in histone 3 genes (H3K27M) characterize a subgroup of deadly
gliomas and decrease genome-wide H3K27 trimethylation. Here we use primary H3K27M
tumor lines and isogenic CRISPR-edited controls to assess H3K27M effects in vitro and
in vivo. We ﬁnd that whereas H3K27me3 and H3K27me2 are normally deposited by PRC2
across broad regions, their deposition is severely reduced in H3.3K27M cells. H3K27me3 is
unable to spread from large unmethylated CpG islands, while H3K27me2 can be deposited
outside these PRC2 high-afﬁnity sites but to levels corresponding to H3K27me3 deposition in
wild-type cells. Our ﬁndings indicate that PRC2 recruitment and propagation on chromatin
are seemingly unaffected by K27M, which mostly impairs spread of the repressive marks it
catalyzes, especially H3K27me3. Genome-wide loss of H3K27me3 and me2 deposition has
limited transcriptomic consequences, preferentially affecting lowly-expressed genes regulating neurogenesis. Removal of H3K27M restores H3K27me2/me3 spread, impairs cell
proliferation, and completely abolishes their capacity to form tumors in mice.
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igh-Grade Gliomas (HGG) are devastating brain tumors
and a major cause of cancer-related mortality1. Pediatric
HGG have molecular signatures distinct from those of
adult HGG2–4. Speciﬁcally, they frequently harbor somatic
mutations in histone 3 (H3) genes5–7. These mutations primarily
impact the epigenome and show neuroanatomical and age speciﬁcity, suggesting that they occur during brain
development1,5,6,8–10. The most frequent oncohistone, H3K27M,
speciﬁes diffuse midline gliomas, which include deadly diffuse
intrinsic pontine gliomas (DIPG) and represents a newly recognized molecular HGG entity in the 2016 World Health Organization classiﬁcation11. This somatic heterozygous mutation is
present in all tumor cells at diagnosis, tumor spread, and in
autopsy samples, and is recognized to be the major oncogenic
driver in these HGGs1,6,10,12,13.
The mechanism of H3K27M action remains unclear. Mutant
H3K27M, which can occur in both the canonical (H3.1 or H3.2)
and non-canonical (H3.3) histone variants, contributes to only a
fraction of the total H3 pool (3–17%)14. However, it has a
dominant effect as it drastically reduces overall levels of the
repressive H3K27me3 mark in cells14–16. In vitro, H3K27M has
been shown to severely affect the enzymatic activity of EZH2, a
core component of the Polycomb Repressive Complex2 (PRC2),
which normally catalyzes H3K27 methylation (reviewed in
ref. 17), possibly through strong binding of the enzyme to
H3K27M-containing nucleosomes, which sequesters and inactivates the complex18,19. How the resulting in vivo loss of
H3K27me3 induces tumorigenesis remains the subject of active
investigations. Several contradictory hypotheses have been proposed, namely preferential recruitment and/or sequestration of
PRC2 on chromatin by K27M mutant nucleosomes14,19–21, preferential recruitment of PRC2 to its strong afﬁnity sites22, or
exclusion of this complex by mutant nucleosomes from its normal sites in mutant cells23. Indeed, studies using H3K27M-DIPG
lines and mouse neural progenitor cells (NPCs) manipulated to
overexpress H3K27M argue that H3K27me3 loss in large genomic areas leads to increased gene expression at bivalent promoters (marked, in the normal state, by both H3K27me3 and
H3K4me3)20,24, while residual H3K27me3 deposition still occurs
at several genomic loci and mediates oncogenesis22. Varying
levels of PRC2 activity across sites have been suggested to account
for these differential effects of H3K27M on distinct genomic loci,
with those strongly binding PRC2 retaining the mark, and the
weaker binding sites losing it in the presence of the mutation22.
Another study suggested that the speciﬁc enrichment of
H3.3K27M-carrying nucleosomes in actively transcribed genomic
regions where H3.3 is preferentially deposited precludes PRC2
recruitment and subsequent H3K27me3 deposition23. In all,
despite many enticing hypotheses, a uniﬁed view on downstream
effects of H3K27M is lacking. One notable limitation of all studies
to date15,20,22,23 is the lack of an isogenic tumor-relevant context
for studying the effects of the mutation. The precise cell of origin
for these tumors remains unknown. Given that H3K27M is
tumorigenic only when introduced in speciﬁc neurodevelopmental windows22,23,25,26, and that H3K27me3 deposition varies
with cellular context and differentiation stage27, it follows that the
absence of an appropriate isogenic background would likely
represent a major confounder. In addition, no data exists on the
more abundant repressive mark H3K27me2, whose production
by PRC2 is similarly affected by H3K27M14, and which may
contribute to K27M tumorigenesis. Moreover, while there is
evidence that H3K27M mutation is the initiating oncogenic
event12, there is a clear requirement for additional speciﬁc
oncogenic partners to drive tumor formation6,9,12,13,28–30. Whether H3K27M is necessary for tumor progression and/or maintenance is not yet known.
2

To address how decreased H3K27me3/me2 levels lead to
tumorigenesis and to examine the requirement of K27M for
tumor maintenance, here we use multiple human primary
pediatric HGG cell lines as a controlled tumor-relevant setting for
the H3K27M mutation in this study. We directly manipulate
H3K27M by overexpressing it in wild-type lines or using CRISPR
editing to remove it from mutant cell lines. We further alter PRC2
by overexpression or pharmacological inhibition. We use epigenome and transcriptome analysis to study the molecular consequences, cell assays to proﬁle proliferation, and a mouse
orthotopic xenograft model to determine the ﬁnal effect of the
mutation on tumorigenicity (Supplementary Fig. 1, Supplementary Table 1). Our data show that PRC2 deposition and propagation on the chromatin are unaffected by K27M. The main effect
of the mutation is in preventing the spread of H3K27me3, and to
a lesser level H3K27me2, from PRC2 binding sites to larger
silencing domains. This epigenetic defect is reversible upon
removal of the H3K27M mutation, suggesting possible reversibility of its functional consequences. Importantly, we show
H3K27M is essential for tumor maintenance as removal of this
mutation in HGG is sufﬁcient to mitigate tumor growth in vivo.
Results
H3K27me2 loss is less marked than H3K27me3 in H3.3K27M.
We used mass spectrometry to assess H3K27 methylation levels
in primary HGG cell lines carrying H3.3K27M (n = 3) or wildtype (n = 3) for this mutation. Massive loss of H3K27me3 was
observed as expected, while a signiﬁcant but less drastic loss of
H3K27me2, and a modest increase in H3.1/H3.2K27me1 were
seen in H3.3K27M cell lines (Fig. 1a). We then used chromatin
immunoprecipitation combined with sequencing (ChIP-seq) to
proﬁle H3K27me3 and H3K27me2 distribution in these cell
lines. Exogenous chromatin spike-in (ChIP-Rx, see methods),
used to quantitate signal intensity, conﬁrmed overall decrease
in H3K27me3/me2 methylation levels in H3K27M cells compared to wild-type HGGs (Supplementary Fig. 1–2, Supplementary Table 2). Analyzing genome-wide distribution of both
marks showed striking differences between K27M and wildtype HGG lines (Fig. 1b, Supplementary Fig. 3a). While
H3K27me3 was distributed in broad domains in wild-type
cells, H3K27M cells showed sharp peaks of H3K27me3 coinciding with loss of the mark in the broad domains where it is
normally found and resembling the pattern of embryonic stemcells (ESC) (Supplementary Fig. 3a). Notably, H3K27me3 distribution was highly consistent across six H3K27M cell lines
tested and comparable to that of the primary tumors from
which the cell lines were derived (Supplementary Fig. 3b-d). In
contrast, the H3K27me2 mark showed a broader distribution
in K27M, resembling the distribution of H3K27me3 in wildtype HGGs, while in these cells not carrying the mutation this
mark spread as expected genome-wide largely outside
H3K27me3 domains (Fig. 1b, c). We further proﬁled PRC2
distribution by ChIP-seq of the core PRC2 component SUZ12.
In H3K27M-mutant cells, H3K27me3 deposition showed nearcomplete co-occupancy with SUZ12, suggesting that
H3K27me3 is restricted in these cells to PRC2 binding sites
(Fig. 1b, c, Supplementary Fig. 4–5). Wild-type HGGs, in
turn, showed additional deposition of H3K27me3 in broad
domains with limited SUZ12 occupancy (Fig. 1b, c, Supplementary Fig. 4–5). Our data indicate that, in the presence of
K27M, H3K27me2 production by PRC2 is decreased but to a
lesser magnitude than H3K27me3. Accordingly, a level
of spread on chromatin is seemingly achieved for this mark
while H3K27me3 deposition appears conﬁned to speciﬁc
genomic loci.
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Fig. 1 H3K27M-mutant pediatric high-grade gliomas (pHGGs) exhibit distinct distribution of H3K27me3 and H3K27me2 a H3K27me1/2/3 abundance
quantiﬁed by mass spectrometry, primary cells (WT n = 3 cell lines, K27M n = 3 cell lines, three replicates for each cell line, mean ± standard deviation,
Student’s t-test). b Example of normalized H3K27me3 and H3K27me2 chromatin immunoprecipitation sequencing (ChIP-seq) tracks of H3K27M and WT
pHGG lines, showing qualitative differences in distribution of these marks. For comparison, SUZ12 ChIP-seq tracks, and CpG islands (CGIs) are shown.
c Heatmap plots of ChIP-seq signal intensity for SUZ12, H3K27me2/3, and DNA methylation (whole-genome bisulphite sequencing (WGBS)) over CGIs
for BT245 (H3K27M) and G477 (WT). CGIs are separated by kmeans clustering (k = 3). d Top: Average enrichment at the top 1% of 1 kb bins for
H3K27me3. Bottom: Proportion of H3K27me3 reads in SUZ12 peaks, CGIs, promoters. H3K27M cells show higher enrichment for H3K27me3 in top 1% 1
kb bins, SUZ12 peaks, CGIs and promoters compared to wild-type cells (mean ± standard deviation, Student’s t-test). e H3K27me3 signal intensity over
partially methylated domain (PMD) regions in BT245 (H3K27M) and G477 (WT) cells, aggregate plot. Source data are provided as a Source Data ﬁle

H3K27me3 is retained at unmethylated CGIs. To obtain a
quantitative characteristic of H3K27me3 distribution, we divided
the genome into 1 kb bins and calculated the average normalized
read counts in top 1% of the most enriched bins (Fig. 1d).
H3K27M cells had signiﬁcantly higher enrichment in top bins,
reﬂecting focused distribution of H3K27me3 mark in those cells
in contrast to broad distribution in wild-type cells. Large unmethylated CpG islands (CGIs) are known high-afﬁnity recruitment
sites for PRC2. We subsequently quantiﬁed the proportion of
H3K27me3 reads within CGIs and SUZ12 peaks and observed a
signiﬁcantly higher percentage of the H3K27me3 signal within
those features for H3K27M cells compared to wild-type (Fig. 1d).
While H3K27me3 was preserved at unmethylated CGIs (Fig. 1b, c),
we noticed that broad domains of H3K27me3 in wild-type cells,
generally coinciding with partially methylated DNA domains
(PMD), were greatly depleted in K27M cells (Fig. 1e, Supplementary Fig. 6). Accordingly, we observed a shift in a proportion
of H3K27me3 from intergenic to promoter regions between wildtype and H3K27M cells (Fig. 1d, Supplementary Fig. 7).
We next investigated the distribution of the H3K27me3 writer
(PRC2) and reader (PRC1) complexes. In all cell lines, PRC2
(SUZ12) was largely localized to unmethylated CGIs (Fig. 1b, c).

However, a visibly broader pattern of SUZ12 around CGIs was
observed in H3K27M cells, contrasting with its narrow deposition
in wild-type lines (Fig. 1c, Supplementary Fig. 4) and consistent
with an increased retention of PRC2 around its binding sites. The
PRC1 complex can recognize H3K27me3 and mediate transcriptional repression but, depending on subunit composition, it can
also bind and regulate active promoters31. We observed that the
core PRC1 subunit RING1B showed increased overlap with
H3K27me3/SUZ12 occupancy at CGIs in H3K27M lines
compared to wild-type (Supplementary Fig. 5).
H3K27M directly affects H3K27me3/me2 spread. We derived
H3K27M mutants by CRISPR-Cas9 in HEK293T (Supplementary
Fig. 8) and overexpression of H3.3K27M in a wild-type HGG line
(G477, Fig. 2a–c, Supplementary Fig. 9). In both lines, we
observed signiﬁcant loss of H3K27me3 (Fig. 2a–c, Supplementary
Fig. 8–9) and conversion of broad domains to narrow peaks,
resembling patterns seen in primary H3K27M-HGG lines
(Fig. 2b, c, Supplementary Fig. 8–9). Accordingly, the proportion
of H3K27me3 increased in CGIs and promoters (Supplementary
Fig. 8–9). Impaired spreading of methylated H3K27 upon K27M
expression is consistent both in wild-type HGG cells and
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Fig. 2 H3K27M reversibly induces global redistribution of H3K27me2 and H3K27me3 (a–c). G477 wild-type cell line with H3.3-K27M overexpression.
a H3K27me2/3 abundance by histone mass spectrometry (n = 3 in each group, mean ± standard deviation, Student’s t-test). b Example ChIP-seq tracks of
H3K27me2/3 distribution, normalized by drosophila spike-in (ChIP-Rx). c Heatmap plots of ChIP-seq signal intensity for H3K27me2 and H3K27me3 over
CGIs for parental G477 (wild-type) and G477 overexpressing K27R and K27M. CGIs are separated by kmeans clustering (k = 3). d–f. BT245 with H3K27M
knockout (KO) by CRISPR/Cas9. d H3K27me3 abundance by histone mass spectrometry (K27M n = 3, KO n = 6, mean ± standard deviation, Student’s ttest). Whiskers represent standard deviation. e Example ChIP-seq tracks of H3K27me2/3 distribution, ChIP-Rx normalized. f Heatmap plots of ChIP-seq
signal intensity for H3K27me2 and H3K27me3 over CGIs for parental BT245 (H3K27M) and K27M knockout (K27M-KO) by CRISPR. CGIs are separated
by kmeans clustering (k = 3). g H3K27me3 signal change at CGIs of BT245, K27M-KO vs. K27M, color coded for DNA methylation. y-axis shows the
difference in normalized H3K27me3 levels at CGIs in K27M vs. K27M-KO (log2), while x-axis shows normalized H3K27me3 levels in non-K27M state
(K27M-KO, log2). Four categories of CGIs based on H3K27me3 levels and difference are depicted by squares. h Strong correlation of H3K27me2 in
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H3K27me2 in H3K27M state (black dotted line). H3K27me3 levels in each bin for non-K27M sample are shown in blue, H3K27me2 levels in non-K27M—
in red (normalized, log2). Source data are provided as a Source Data ﬁle

HEK293T, an unrelated differentiated cell type, demonstrating
this effect is independent of cell context and is directly linked to
the mutation. Interestingly, when assessing H3K27me2 deposition in H3.3K27M-expressing G477, this mark showed signiﬁcantly less broad deposition, while its genome-wide
distribution was strikingly similar to that of H3K27me3 in the
parental G477 line (Fig. 2b, c). This further supports our observation that the effect of K27M appears more pronounced on
H3K27me3 deposition than on H3K27me2.
4

To study the mutation in a controlled, tumor-relevant context,
we removed the K27M mutant allele from two HGG lines, BT245
and DIPGXIII (SU-DIPGXIII), using the CRISPR/Cas9 system
(Supplementary Fig. 10–11). Edited clones (H3K27M-KO)
showed an average ﬁve-fold increase in H3K27me3 and a 2–3fold increase in H3K27me2 levels (Fig. 2d, Supplementary
Fig. 10–11). This was accompanied by spread of H3K27me3
and H3K27me2 signals into broad domains, resembling those of
wild-type HGG cell lines (Fig. 2e, f, Supplementary Fig. 10–11),
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and subsequent decrease in the proportion of H3K27me3 reads in
promoters and CGIs (Supplementary Fig. 10–11). A number of
unmethylated CGIs (Fig. 2g, Supplementary Fig. 10, 12–13) had
low to absent H3K27me3 levels both in the original mutant cell
lines and in isogenic H3K27M-KO, which generally corresponded
to active promoters marked by H3K27ac (absent). Also, a number
of unmethylated CGIs with no H3K27me3 in H3K27M cells (lost)
showed deposition of the mark in H3K27M-KO. Notably, the
degree of loss in H3K27M cells was positively correlated with the
levels of the mark on that site in H3K27M-KO edited cells.
Importantly, the large unmethylated CGIs enriched for SUZ12,
where most of H3K27me3 is deposited in H3K27M cells, retained
the mark (retained), which spread from these sites in H3K27MKO cells (Fig. 2g, Supplementary Fig. 10, 12–13). The relatively
broad enrichment of SUZ12 in these regions in H3K27M became
more focused in H3K27M-KO cells, similar to the SUZ12 pattern
observed in wild-type HGG (Supplementary Fig. 12, 14). Very
few CGIs acquired higher H3K27me3 levels in the presence of
H3K27M (gained); these gained regions were distinct in each
edited line (Supplementary Table 3), and thus likely represent
secondary downstream effects of unclear signiﬁcance. Interestingly, the CDKN2A (p16) locus, a candidate driver gene in K27M
gliomas22, retained high-levels of H3K27me3, regardless of the
presence of the H3K27M mutation (Supplementary Fig. 15).
Finally, H3K27me3 retention has been proposed to correspond to
regions of H3K27M deposition19. However, levels of H3K27me3
and H3K27M did not positively correlate in our cell lines or in a
mouse model26 of H3K27M tumorigenesis (Supplementary
Fig. 16). Thus, H3K27M redistributes H3K27me3 to follow
PRC2 recruitment, but not H3.3/K27M deposition. In addition,
the H3K27me2 mark spreads outside CGIs in H3.3K27M mutant
cells. Notably, when comparing H3K27M lines to their isogenic
CRISPR-edited lines, we observe that it is conﬁned in mutant cells
to regions of H3K27me3 spread in H3.3K27M-KO lines (Fig. 2e,
f, Supplementary Fig. 11) similar to what we observed in
H3.3K27M G477 cells (Fig. 2b, c). Indeed, a strong correlation
between H3K27me2 in K27M and H3K27me3 in wild-type
isogenic cells is seen (Fig. 2h). Overall, these ﬁndings, together
with our data on H3K27M-KO or H3.3K27M-expressing wildtype HGG, indicate that H3K27M decreases H3K27me3 and to a
lower extent K27me2 levels and deposition. Importantly, while
H3K27me3 is conﬁned to speciﬁc and narrow regions corresponding to large unmethylated CGIs marked with PRC2,
H3K27me2 is able to spread outside these domains in the
presence of the mutation. Unlike H3K27me3, di-methylation of
H3K27 is enzymatically easier for the PRC2 complex and can be
produced by transient interactions with the chromatin32,33,
possibly accounting for the differential effects we observe for
both marks in our model systems.
H3K27M does not sequester PRC2 on chromatin. Pediatric
HGG have no known mutations in PRC2 components6,9,34,
suggesting the effect of H3K27M may be distinct from complete
loss of PRC2 function. Moreover, small molecule PRC2 inhibitors
impair the growth of H3K27M lines22. We replicated this in our
model system where we treated H3K27M-HGG and isogenic
H3K27M-KO cell lines using two EZH2 inhibitors and found
signiﬁcantly more growth inhibition in the presence of K27M
(Supplementary Fig. 17). Pharmacological EZH2 inhibition
drastically decreases H3K27me3 and H3K27me2 marks and
uniformly affects their deposition and spread in both lines
(Fig. 3a, b, Supplementary Fig. 17). In contrast, the effect of
H3K27M is more pronounced on H3K27me3 deposition, which
is then restricted to CGIs, therefore suggesting that the mutation
does not fully phenocopy PRC2 inhibition. Next, we tested
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whether we could rescue H3K27M-induced effects by overexpressing either: (1) wild-type EZH2 or (2) EZH2-Y641N, a
preferential di- to tri-methylase mutant35 shown to be less sensitive to inhibition by H3K27M14. Overexpression of wild-type
EZH2 had minor effects on H3K27me3 and H3K27me2 (~1.5fold gain) suggesting that increased EZH2 levels are unable to
overcome K27M-induced conﬁnement of both marks (Supplementary Fig. 18). Strikingly, EZH2-Y641N induced a large gain of
H3K27me3 (~7-fold). Notably, this was achieved by the spread of
H3K27me3 from sites retaining the mark in H3K27M cells on
corresponding domains showing H3K27me2 spread in
H3.3K27M mutant cells (Fig. 3c–e, Supplementary Fig. 18).
Accordingly, a drastic depletion of H3K27me2 in H3.3K27M
mutant cells overexpressing EZH2-Y641N was observed in these
regions (Fig. 3c, Supplementary Fig. 18). As no new PRC2
nucleation sites were generated, our overall data further support
that H3K27M induces defective spread of H3K27me3/me2, which
is more pronounced for H3K27me3. Importantly, H3.3K27M
does not appear to retain the PRC2 complex at CGIs, as we
observe spread of H3K27me2 despite the presence of the mutation, while spread of the H3K27me3 mark is possible in this
setting when overexpressing EZH2-Y641N.
H3K27M induces limited transcriptomic changes. To assess
speciﬁc effects of H3K27M mutation on gene expression, we
compared the transcriptomes of isogenic lines in the presence or
absence of H3K27M (G477, HEK293T, BT245, DIPGXIII). We
correlated changes in gene expression with promoter H3K27me3
levels. Although H3K27me3 is lost in wide genomic areas, the
resulting effect on transcription in H3K27M-mutant cells is
relatively modest. Indeed, most genes had no H3K27me3
(Absent) or no change in H3K27me3 levels (Retained) on their
promoter regardless of H3K27M (Fig. 4a). As expected, we
observed limited changes in their expression. Despite the loss of
H3K27me3 on a large number of promoters in the context of
H3K27M (Lost), only a modest fraction of associated genes
showed differential expression, mainly upregulation. Moreover,
very few genes had a gain of promoter H3K27me3 (Gained) in
H3K27M-expressing cells, only a small fraction of which were
downregulated (Fig. 4b). In all our model systems—irrespective of
whether H3K27M was introduced or removed—the presence of
H3K27M resulted in overall transcriptional derepression characterized by an excess of upregulated genes (Fig. 4b, c). Interestingly, the number of upregulated genes was highest within the
low-expression range (Fig. 4c), suggesting that one of the effects
of H3K27M on the transcriptome is to disable proper H3K27me3
repression and permit low levels of aberrant transcription. To
identify potential driver targets/pathways in H3K27M mutagenesis, we investigated the genes that were signiﬁcantly affected by
knockout of H3K27M in both BT245 and DIPGXIII cells (Supplementary Table 4). In the presence of H3K27M, we found more
upregulated (102) than downregulated (12) genes, reﬂecting the
overall trend of gene derepression. Pathway analysis on the
downregulated set did not identify any Gene Ontology (GO)
enrichment, but the upregulated set showed overrepresentation of
genes involved in neural differentiation and developmental
pathways, consistent with previous observations in other
systems22,25,26 (Fig. 4d). Notably, across all three HGG lines, the
presence of H3K27M-induced upregulation of ID1-ID4 genes
(Supplementary Fig. 19). These ID (inhibitors of DNA binding/
differentiation) genes are broadly implicated in developmental
processes, inhibition of differentiation, maintenance of selfrenewal, and multipotency in stem cells. ID genes have been
shown to be upregulated in response to growth factor receptor
stimulation, including ACVR1, a receptor activated in 20% of
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Fig. 3 EZH2 inhibition does not completely mimic H3K27M effects and EZH2-Y641N partly overcomes H3K27M-induced effects (a, b). Changes in
H3K27me2/3 levels and distribution upon EZH2 inhibition. a Example ChIP-seq tracks of H3K27me2/3 distribution in G477 (wild-type) and BT245
(H3K27M) cell lines treated and not treated with UNC1999 (EZH1/2 inhibitor), ChIP-Rx normalized. For comparison, G477 cell line with H3.3-K27M
overexpression is also included. b Heatmap plots of ChIP-seq signal intensity for H3K27me2 and H3K27me3 over CGIs for G477 cell line (wild-type)
treated and not treated with UNC1999, as well as with H3.3-K27M overexpression. CGIs are separated by kmeans clustering (k = 3). c–e Changes in
H3K27me2/3 levels and distribution upon overexpression of EZH2-wt and EZH2-Y641N. c Example ChIP-seq tracks (ChIP-Rx normalized) of H3K27me2/
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DIPGs9,28–30. Thus, H3K27M-HGG can promote an undifferentiated cellular state through aberrant expression of ID genes
due to both K27M or ACVR1 mutations.
H3K27M is required for tumorigenesis. We examined the
consequences of the introduction and removal of the H3K27M
mutation on cell proliferation in vitro, as well as on tumor growth
in orthotopic xenograft models (PDOX). In vitro, across the three
tumor cell lines, we observed a consistent trend of H3K27M
conferring a proliferative advantage (Supplementary Fig. 20a). In
BT245, where H3K27M removal has the strongest effect, we were
able to rescue the decrease in growth rate when we re-expressed
the mutation (Supplementary Fig. 20b). To investigate the
requirement of H3K27M for tumor growth in vivo, we injected
independently edited BT245 and DIPGXIII (H3K27M-KO) clonal lines in the brains of NSG mice. As positive controls, for both
BT245 and DIPGXIII, we performed parallel injections with two
H3K27M-mutant lines (one parental and one unedited). We have
previously successfully propagated BT245 and DIPGXIII as
PDOX in numerous experiments and, as expected, mice injected
with the positive control H3K27M lines progressively developed
tumors resembling HGG. However, none of the mice injected
with H3K27M-KO cells developed tumors during follow-up of
over 1 year for BT245 and 6 month for DIPGXIII (Fig. 5a,
6

Supplementary Fig. 20c), despite the presence of other highly
oncogenic mutations in the injected cells (TP53 in both parental
lines, TERT promoter mutation and C-MYC ampliﬁcation present in the BT245 parental line, N-MYC ampliﬁcation in
DIPGXIII line). Our data strongly indicate that the H3K27M
mutation is not only necessary for initial stages of tumor establishment but also continuously needed to preserve the proliferative and tumorigenic potential of these tumors.
Discussion
We provide evidence that H3K27M impairs the production and
the spread of the repressive H3K27me3 mark from PRC2 highafﬁnity sites (Fig. 5d). We observe non-random decrease of
H3K27me3 in the presence of the mutation, with residual
deposition conﬁned to large unmethylated CGIs enriched for
PRC2. Notably, we show that the production and the distribution
of H3K27me2, a repressive mark that is abundantly deposited by
PRC2 across the silent euchromatin and the basis from which this
complex synthesizes H3K27me332,33, are also affected by
H3.3K27M, albeit at a lower magnitude than H3K27me3.
Importantly, in H3.3K27M mutant cells, H3K27me2 spreads
outside unmethylated CGIs, mirroring H3K27me3 distribution in
wild-type cells, indicative that the PRC2 complex is not retained
at these CGIs. Introducing H3K27M in HGG cell lines wild-type
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Fig. 4 Transcriptome and H3K27me3 loci implicate H3K27M in neural differentiation a H3K27me3 level difference plot in BT245 dataset, color coded by
gene expression changes (green for upregulated in K27M state, purple—downregulated, grey—no signiﬁcant change in expression). y-axis shows the
difference in normalized H3K27me3 levels at promoters in K27M vs. K27M-KO (log2), while x-axis shows normalized H3K27me3 levels in non-K27M
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for this mutation and in HEK293T cells reproduces decreased
production and conﬁnement of both marks (H3K27me3 to CGIs,
H3K27me2 to spread of H3K27me3 in wild-type cells). We further show that defective H3K27me3/me2 spread induced by
K27M is reversible. When the mutation is removed, uninhibited
PRC2 restores deposition of H3K27me3 from these large CGIs to
sites that had lost it, mainly intergenic sites and PMDs with poor
PRC2 recruitment, while H3K27me2 distribution becomes comparable to that seen in wild-type HGGs. Additionally, Y641NEZH2, an EZH2 mutant less sensitive to H3K27M inhibition
which catalyzes me2/me314, restores deposition of H3K27me3 by
extending it from existing PRC2 recruitment sites, without
creating new sites, similar to what we observe in H3K27M-KO
isogenic cells. This further argues against retention of the PRC2
complex at given genomic loci and supports a K27M-induced
defective spread of both H3K27me2 and H3K27me3 repressive
marks.

Several recent reports on PRC2 function support our ﬁndings
that decreased catalysis of K27me3/me2 due to K27M results in a
defective spread on chromatin of these repressive marks from
PRC2 high-afﬁnity sites. In one study, newly deposited
H3K27me3 and me2 progress from PRC2 high-afﬁnity sites
recruiting the complex following total erasure36. This observation
is in keeping with our ﬁndings that most of the retained
H3K27me3 peaks in H3K27M cells correspond to unmethylated
CGIs, while H3K27me2 spreads from these sites, even though at
lower magnitude compared to wild-type cells. This indicates that
the PRC2 complex is not retained by the mutation and can still
spread on chromatin. The differential effects observed for
K27me2 and K27me3 are probably due to differential catalytic
constraints for PRC2 when depositing these marks. Indeed,
production of H3K27me2 is enzymatically easier and seems to
require transient interactions on the chromatin for the complex
as compared to H3K27me3, which is produced from H3K27me2
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and requires a more stable association with PRC219,37. This may
also account for the broader distribution of SUZ12 in H3K27Mmutant cells and the near-complete overlap with H3K27me3 we
observe at unmethylated CGIs. Lack of distribution of H3K27me3
from PRC2 recruitment high-afﬁnity sites, may also be partly due
to poor allosteric activation of EZH2 following decreased production of H3K27me3 in the presence of K27M, which would
further preclude the spread of the repressive mark. Indeed, EED is
an essential subunit of PRC2 that recognizes initial H3K27me3
and allosterically activates the complex, promoting further
deposition of the mark38. Also, an EED cage mutant that prevents
H3K27me3 recognition by PRC2 was shown to induce similar
conﬁnement of H3K27me339, indicating a potential effect of
K27M in impairing allosteric activation of PRC2. Further
experiments are needed to support decreased allosteric activation
of EED as a consequence of K27M mutagenesis. In addition, the
lack of H3K27me2 deposition in H3K27M cells outside typical
H3K27me3 domains could be due to the presence of other histone marks such as H3K36me2 in those regions. This defect in
spread of the marks, but not recruitment or spread of PRC2, is
further supported by the dynamic deposition of H3K27me3 at
novel loci in response to external stimuli that we (Supplementary
Fig. 15 and26) and others22 observe, despite the presence of the
mutation. These suggest that in H3K27M cells, PRC2 could be
recruited to locally as needed to deposit H3K27me3 as the effect
required does not involve spread of the mark.
Experimental results obtained with the pharmacological inhibition of EZH2 indicates that the mutation does not fully
reproduce pharmacological EZH2 inhibition in K27M wild-type
HGG lines. In addition, speciﬁc retention of H3K27me3 in
H3K27M lines suggests regional functional requirement for
8

H3K27me3, and may explain their sensitivity to these EZH2
inhibitors that we and others22 observe, as these cells may not be
able to tolerate further loss of the mark. Interestingly, while
K27M induces widespread loss of H3K27me3, only a modest
proportion of genes that lose the mark at their promoters are
dysregulated. One explanation of such modest transcriptional
dysregulation could be the observation that in H3K27M cells,
H3K27me2 occupies the regions that lost H3K27me3 and it
might maintain certain level of gene silencing. We propose that
the changes observed in the presence of H3K27M consist predominantly of low-level transcriptional derepression that results
from incomplete silencing. Dysregulated genes showed overrepresentation of functions involved in stemness and neurogenesis, in keeping with recent results suggesting that K-M mutations
on H3K27 or K36 induce transcriptional deregulation affecting
cell differentiation40. In normally developing cells, lineage
commitment and further cell differentiation is mediated by
a multitude of epigenetic changes, including an interplay
of acquisition or loss of H3K27me3 and me2 at multiple sites,
with increased H3K27me3 deposition needed upon cellular
differentiation24,27,41. While normal cells can dynamically regulate this mark to differentiate, H3K27M-HGG have severely
impaired H3K27me3 production and show its conﬁnement to
speciﬁc CGIs, not allowing the mark to fully silence neighboring
regions and thus possibly stalling further differentiation. The
CGIs retaining H3K27me3, from which the mark would have
spread in the absence of H3K27M, may thus represent original
binding sites in committed NPCs, as suggested by the blockade in
neurogenesis and brain developmental pathways we observe in
K27M HGG and in keeping with recent data indicating an oligodendroglial progenitor cell as a potential cell of origin for these
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HGG25,26,37,42. Notably, our results mirror ﬁndings in ES cells,
which show similar restriction of H3K27me3 to CGIs, and where
loss of PRC2 does not promote major transcriptional changes but
stalls further differentiation and lineage speciﬁcation.
There is an ongoing debate regarding the requirement of
H3K27M in maintaining tumorigenesis. Our data show that the
removal of K27M is sufﬁcient to abolish tumor formation in an
in vivo orthotopic mouse model. Indeed, despite the presence of
other oncogenic lesions, including TERT promoter mutation,
TP53 alterations, and C-MYC or N-MYC ampliﬁcation, no
tumors formed in the brain of mice injected with HGG cells
rendered wild-type for the H3K27M mutation. The mice were
followed for over 6 months to one year to exclude the possibility
of delayed tumor onset. The K27M mutation is thus not simply a
remnant of initial stages of tumorigenesis, it seems to be continuously required for both tumor formation and maintenance.
In summary, we propose a model where the K27M mutation
affects H3K27me3 and H3K27me2 production and the relative
spread of both these repressive marks from initial PRC2 binding
sites in the cell of origin. Neither the recruitment of PRC2 to its
nucleation sites nor the deposition of the H3K27me3 mark in the
proximity of those sites is affected by the mutation. However, as
the marks cannot spread to establish the proper silencing landscape, further lineage speciﬁcation, a major role of PRC2, is not
possible, and the cell is stalled in an early epigenetic and progenitor state, indeﬁnitely multiplying without being able to further differentiate. Over time, this will allow acquisition of other
genetic alterations ultimately leading to tumor formation. We
propose that H3K27M has a vital role for maintaining this speciﬁc epigenomic landscape that prevents further cell differentiation. This in turn allows for tumor formation and is necessary for
tumor maintenance, making H3K27M an important therapeutic
target in HGG. Compounds targeting this mutation, when
available, have the potential to greatly improve survival in this
deadly cancer.
Methods
Patient samples and clinical information. This study was approved by the
Institutional Review Board of the respective institutions from which the samples
were collected. We thank Keith Ligon and Michelle Monje for generously sharing
primary tumor cell lines established from patients with high-grade glioma.

Cell culture. Tumor-derived cell lines were maintained in Neucult NS-A proliferation media (StemCell Technologies) supplemented with bFGF (10 ng/mL)
(StemCell Technologies), rhEGF (20 ng/mL) (StemCell Technologies), and heparin
(0.0002%) (StemCell Technologies) on plates coated in poly-L-ornithine (0.01%)
(Sigma) and laminin (0.01 mg/mL) (Sigma). HEK293T cells (ATCC) were cultured
in DMEM containing 4.5 g/L glucose, L-glutamine, phenol red, and 10% FBS
(Wisent). All lines tested negative for mycoplasma contamination, checked
monthly using the MycoAlert Mycoplasma Detection Kit (Lonza). Tumor-derived
cell lines (Supplementary Table 1) were conﬁrmed to match original samples by
STR ﬁngerprinting.

CRISPR/Cas9 genome editing. pSpCas9(BB)-2A-GFP (PX458) was a gift from
Feng Zhang (Addgene plasmid # 48138). pSpCas9n(BB)-2A-GFP (PX461) was a
gift from Feng Zhang (Addgene plasmid # 48140).
CRISPR-Cas9 editing was carried out as described in ref. 43. Constructs were
transfected with lipofectamine 2000 (Thermo Fischer Scientiﬁc) according to the
manufacturer’s protocol. Flow cytometry sorted single GFP + cells in 96-well
plates, 72-h post-transfection. A summary of the FACS gating strategy is provided
in the Source Data File. Clones were expanded and the target locus sequenced by
Sanger sequencing. Selected clones were screened by Illumina MiSeq system for the
target exon to conﬁrm complete mutation of the K27M allele. Mass spectrometry
conﬁrmed the absence of K27M mutant peptide in these clones.
In HEK293T cells, clones heterozygous for HIST1H3B-K27M were derived
through use of PX461 with the guide sequence and repair template in
Supplementary Table 5. In primary HGG lines heterozygous for H3F3A-K27M,
clones were derived with the mutant allele edited using PX458 and the guide
sequence in Supplementary Table 5.

Lentiviral transduction. Lentiviruses were gifts from Dr. Peter Lewis. EZH2-WT
and EZH2-Y641N constructs were applied to cells for 24 h, and puromycin
(Wisent) selection (2 ug/mL) was maintained for the duration of growth. Lentiviruses expressing H3.3-K27R and H3.3-K27M were applied for 24 h and G418
(Wisent) selection (500 ng/mL) was maintained for the duration of growth.
Western blotting. Cells were lysed using RIPA buffer with added protease inhibitors (Roche). Whole lysate protein concentration was determined with the
Bradford assay reagent (Bio-Rad). Ten micrograms of protein was separated on
NuPAGE 3–8% Tris Acetate Protein gels (ThermoFischer Scientiﬁc) and wettransferred to a nitrocellulose membrane (Bio-Rad). Membrane blocking was
performed with 5% skim milk in tris buffered saline (50 mM Tris, 150 mM NaCl,
0.1% Tween 20, pH 7.4) (TBST) for 1 h. Membranes were incubated overnight with
primary antibody solutions in 1% skim milk in TBST: anti-EZH2 ((1:1000, CST
5246), anti-H3K27M (1:200, Millipore ABE419), anti-H3K27me3 (1:1000, Millipore ABE44), anti-total H3 (1:2000, Abcam 1791), and anti-beta-actin (1:1000,
CST 4970), also listed in Supplementary Table 6. Membranes were washed three
times in TBST, and the ECL anti-rabbit IgG Horseradish Perixidase linked whole
antibody (GE Healthcare) was applied for 1 h, at 1:1000 dilution in 1% skim milk in
TBST. Membranes were washed three times and the signal was resolved with
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare) and
imaged on a ChemiDoc MP Imaging System (Bio-Rad). Uncropped versions of all
blots are provided in Source Data ﬁle.
Histone modiﬁcation identiﬁcation and quantiﬁcation with nLC-MS. The
complete workﬂow for histone extraction, LC/MS, and data analysis was recently
described in detail44. Brieﬂy, cell pellets (~1 × 106 cells) were lysed on ice in nuclear
isolation buffer supplemented with 0.3% NP-40 alternative. Isolated nuclei were
incubated with 0.4 N H2SO4 for 3 h at 4 °C with agitation. Hundred percent
trichloroacetic acid (w/v) was added to the acid extract to a ﬁnal concentration of
20% and samples were incubated on ice overnight to precipitate histones. The
resulting histone pellets were rinsed with ice cold acetone + 0.1% HCl and then
with ice cold acetone before resuspension in water and protein estimation by
Bradford assay. Approximately 20 µg of histone extract was then resuspended in
100 mM ammonium bicarbonate and derivatized with propionic anhydride. One
microgram of trypsin was added and samples were incubated overnight at 37 °C.
After tryptic digestion, a cocktail of isotopically-labeled synthetic histone peptides
was spiked in at a ﬁnal concentration of 250 fmol/µg and propionic anhydride
derivatization was performed for second time. The resulting histone peptides were
desalted using C18 Stage Tips, dried using a centrifugal evaporator, and reconstituted using 0.1% formic acid in preparation for nanoLC-MS analysis.
nanoLC was performed using a Thermo ScientiﬁcTM Easy nLCTM 1000
equipped with a 75 µm × 20 cm in-house packed column using Reprosil-Pur C18-AQ
(3 µm; Dr. Maisch GmbH, Germany). Buffer A was 0.1% formic acid and Buffer B
was 0.1% formic acid in 80% acetonitrile. Peptides were resolved using a two-step
linear gradient from 5 to 33% B over 45 min, then from 33 to 90% B over 10 min at a
ﬂow rate of 300 nL/min. The HPLC was coupled online to an Orbitrap Elite mass
spectrometer operating in the positive mode using a Nanospray Flex™ Ion Source
(Thermo Scientiﬁc) at 2.3 kV. Two full MS scans (m/z 300–1100) were acquired in the
orbitrap mass analyzer with a resolution of 120,000 (at 200 m/z) every 8 DIA MS/MS
events using isolation windows of 50 m/z each (e.g., 300–350, 350–400, …,650–700).
MS/MS spectra were acquired in the ion trap operating in normal mode.
Fragmentation was performed using collision-induced dissociation (CID) in the ion
trap mass analyzer with a normalized collision energy of 35. AGC target and
maximum injection time were 10e6 and 50 ms for the full MS scan, and 10e4 and 150
ms for the MS/MS can, respectively. Raw ﬁles were analyzed using EpiProﬁle.
Cell proliferation assays. Cell lines were plated at low conﬂuency in either 12- or
24-well plates. Cell number was counted every 7 days using a Cellometer Auto T4
bright ﬁeld cell counter (Nexcelom Bioscience). Cell index is reported as an average
cell count of at least three biological replicates, normalized to a control group. For
CRISPR-edited lines, a minimum of two distinct clones per group were included in
experiments.
Drug sensitivity assay. Cells were plated at a density of 7000 cells per well in 96well plate. They were treated with an increasing dose of EZH2 inhibitors, GSK343
and UNC1999, obtained from the Structural Genomic Consortium, ranging from
0.5 to 10uM. DMSO was used as a vehicle control. Cells were incubated with the
drugs for 7 days and media was changed every 3 days. In order to assess cell
viability, Alamar blue was added on cells on the seventh day for 6 h and absorbance
at 570 nm and 600 nm was determined using i-Control microplate reader software
by Tecan. Ratio of cell viability was calculated according to the following formula
for measuring cytotoxicity and proliferation:
Percentage difference between treated and control cells
ðO2  A1Þ  ðO1  A2Þ
 100
ðO2  P1Þ  ðO1  P2Þ
where, O1 indicates molar extinction coefﬁcient (E) of oxidized Alamar Blue
(Blue) at 570 nm (80586), O2 indicates E of oxidized Alamar Blue at 600 nm
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(117216), A1 absorbance of test wells at 570 nm, A2 absorbance of test wells at
600 nm, P1 absorbance of positive growth control well (cells plus Alamar Blue but
no test agent) at 570 nm, P2 absorbance of positive growth control well (cells plus
Alamar Blue but no test agent at 600 nm.
Graphs were plotted using Graphpad software using mean of three different
replicates. Bars represent standard error of means.
Mouse orthotopic xenograft. All mice were housed, bred, and subjected to listed
procedures according to the McGill University Health Center Animal Care
Committee and were in compliance with the guidelines of the Canadian Council on
Animal Care. Female NOD SCID mice (4–6 weeks) were used for xenograft
experiments. Mice were injected with the following cell lines at a density of 105 cells
in the caudate putamen for BT245: (1) BT245 parental cells (n = 9), (2) BT245
Clone C1 (unedited cells, n = 9), (3) BT245 Clone C4 (K27M-KO clone, n = 9), (4)
BT245 Clone D2 (K27M-KO clone, n = 10), and 7.105 cells in the pons for
DIPGXIII: (1) DIPGXIII parental cells (n = 3), (2) DIPGXIII K27M-KO (n = 3).
The Robot Stereotaxic machine from Neurostar was used for stereotaxic injections.
Mice were monitored daily for over a year, for neurological symptoms of brain
tumors: weight loss, epilepsy, altered gait, lethargy. Mice brains were imaged by
MRI when symptoms appeared. They were euthanized immediately when clinical
endpoint is reached. The brains were removed and put in formalin for histology.
Kaplan–Meier curve for mice survival was generated using the Graphpad software.
Mice that died due to a tumor are considered as 1. Those that were still surviving at
the end of the experiment, or those that were euthanized for non-tumor related
reasons were considered as 0.
Droplet digital PCR. RNA was extracted from cells using the Aurum Total RNA
Mini Kit (Bio-Rad) and concentration was quantiﬁed on the BioDrop uLite
(Montreal Biotech). cDNA was generated using iScript Reverse Transcription
Supermix (Bio-Rad). Target concentration was determined using the QX200
ddPCR EvaGreen Supermix assay (Bio-Rad) using 20 uL per reaction containing
0.5 ng of cDNA, using manufacturer’s protocol cycling conditions with a 58
degrees annealing temperature and 40 cycles. Droplets were assayed using the
QX200 Droplet Reader (Bio-Rad) and manually scored for positive signal using
QuantaSoft Software (Bio-Rad). The concentration of positive droplets per target
was normalized to the concentration of GAPDH. The relative mRNA abundance is
shown as the average of three biological replicates (distinct passages of each cell
line) determined by a single technical replicate. Primer sequences for each target
are found in Supplementary Table 7.
ChIP-sequencing. Cells (cell lines or dissociated tumor cells) were ﬁxed with 1%
formaldehyde (Sigma). Fixed cell preparations were washed, pelleted and stored at
−80 °C. Sonication of lysed nuclei (lysed in a buffer containing 1% SDS) was
performed on a BioRuptor UCD-300 for 60 cycles, 10 s on 20 s off, centrifuged
every 15 cycles, chilled by 4 °C water cooler. Samples were checked for sonication
efﬁciency using the criteria of 150–500 bp by gel electrophoresis. After the sonication, the chromatin was diluted to reduce SDS level to 0.1% and before ChIP
reaction 2% of sonicated drosophila S2 cell chromatin was spiked-in the samples
for quantiﬁcation of total levels of histone mark after the sequencing (see below).
ChIP reaction for histone modiﬁcations was performed on a Diagenode SX-8G
IP-Star Compact using Diagenode automated Ideal ChIP-seq Kit. Twenty-ﬁve
microliter Protein A beads (Invitrogen) were washed and then incubated with
antibodies (anti-H3K27M (1:66, Millipore ABE419), anti-H3K27me3 (1:40, CST
9733), anti-H3K27me3 (1:100, Active Motif 61017), anti-H3K27me2 (1:50, CST
9728), anti-H3.3 (1:66, Millipore 09–838), anti-HA(1:100, CST 3724)) as listed in
Supplementary Table 6, and 2 million cells of sonicated cell lysate combined with
protease inhibitors for 10 h, followed by 20 min wash cycle with provided wash
buffers.
ChIP reaction for SUZ12 and RING1B was performed as follows: antibodies
(anti-SUZ12 (1:150, CST 3737), anti-RING1B (1:200, Active Motif 39663)), also
listed in Supplementary Table 6) were conjugated by incubating with 40 ul protein
A or G beads at 4 °C for 6 h, then chromatin from ~4 million cells was added in
RIPA buffer, incubated at 4 °C o/n, washed using buffers from Ideal ChIP-seq Kit
(one wash with each buffer, corresponding to RIPA, RIPA + 500 mM NaCl, LiCl,
TE), eluted from beads by incubating with Elution buffer for 30 min at room
temperature.
Reverse cross linking took place on a heat block at 65 °C for 4 h. ChIP samples
were then treated with 2 ul RNase Cocktail at 65 °C for 30 min followed by 2 ul
Proteinase K at 65 °C for 30 min. Samples were then puriﬁed with QIAGEN
MiniElute PCR puriﬁcation kit as per manufacturers’ protocol. In parallel, input
samples (chromatin from about 50,000 cells) were reverse crosslinked and DNA
was isolated following the same protocol.
Library preparation was carried out using Kapa HTP Illumina library
preparation reagents. Brieﬂy, 25 ul of ChIP sample was incubated with 45 ul end
repair mix at 20 °C for 30 min followed by Ampure XP bead puriﬁcation. A tailing:
bead bound sample was incubated with 50 ul buffer enzyme mix for 30 °C 30 min,
followed by PEG/NaCl puriﬁcation. Adaptor ligation: bead bound sample was
incubated with 45 ul buffer enzyme mix and 5 ul of different TruSeq DNA adapters
(Illumina) for each sample, for 20 °C 15 min, followed by PEG/NaCl puriﬁcation
10

(twice). Library enrichment: 12 cycles of PCR ampliﬁcation. Size selection was
performed after PCR using a 0.6 × /0.8x ratio of Ampure XP beads (double size
selection) set to collect 250–450 bp fragments.
ChIP libraries were sequenced using Illumina HiSeq 2000, 2500, or 4000 at 50
bp single reads.
RNA-seq. Total RNA was extracted from cell pellets and mouse tumors using the
AllPrep DNA/RNA/miRNA Universal Kit (Qiagen) according to instructions from
the manufacturer. Library preparation was performed with ribosomal RNA (rRNA)
depletion according to instructions from the manufacturer (Epicentre) to achieve
greater coverage of mRNA and other long non-coding transcripts.
Paired-end sequencing (100 bp) was performed on the Illumina HiSeq 2500 or
4000 platform.
Whole-genome bisulphite sequencing. Whole-genome sequencing libraries were
generated from 700 to 1000 ng of genomic DNA spiked with 0.1% (w/w) unmethylated λ DNA (Promega) previously fragmented to 300–400 bp peak sizes using
the Covaris focused-ultrasonicator E210. Fragment size was controlled on a
Bioanalyzer DNA 1000 Chip (Agilent) and the KAPA High Throughput Library
Preparation Kit (KAPA Biosystems) was applied. End repair of the generated
dsDNA with 3′ or 5′ overhangs, adenylation of 3′ ends, adaptor ligation, and cleanup steps were carried out as per KAPA Biosystems’ recommendations. The
cleaned-up ligation product was then analyzed on a Bioanalyzer High Sensitivity
DNA Chip (Agilent) and quantiﬁed by PicoGreen (Life Technologies). Samples
were then bisulﬁte converted using the Epitect Fast DNA Bisulﬁte Kit (Qiagen)
according to the manufacturer’s protocol. Bisulﬁte-converted DNA was quantiﬁed
using OliGreen (Life Technologies) and, based on quantity, ampliﬁed by 9–12
cycles of PCR using the Kapa Hiﬁ Uracil + DNA polymerase (KAPA Biosystems)
according to the manufacturer’s protocol. The ampliﬁed libraries were puriﬁed
using Ampure XP Beads (Beckman Coulter), validated on Bioanalyzer High Sensitivity DNA Chips, and quantiﬁed by PicoGreen.
Sequencing of the WGBS libraries was performed on the Illumina HiSeq2500/
HiSeqX system using 125 or 150-bp paired-end sequencing.
Analysis of ChIP-seq data. Raw reads were aligned to human (UCSC hg19) or
mouse (UCSC mm10) and Drosophila (UCSC dm6) genome build using BWA45
version 0.7.17 with default parameters.
We divided genome into three different types of bins: 1 kb, 10 kb, and 100 kb,
and counted number of reads from ChIP-seq experiments in those bins. We also
counted reads in CpG islands (CGIs), promoters, and genic regions. All the read
counting was done using bedtools46 version 2.22.1. The annotations of CGIs,
promoters, and RefSeq transcripts for hg19 and mm10 genomes were downloaded
from UCSC Table Browser. Promoters were deﬁned as 5 kb regions centered on
RefSeq TSS. For genic regions, we took the region with the longest length of (TESTSS) if multiple TSS and/or TES exist.
Top 1% bin scores were calculated as follows. After alignment, genome was
divided into 1 kb bins. Then ChIP-seq RPKM values were calculated for each bin
(for H3K27me3 and input), and input was subtracted (i.e., H3K27me3—input).
The bins were sorted by these values, and average value of top 1% bins was taken.
The data manipulation was performed in R.
As known, ChIP-seq enrichments are qualitative measures and cannot be
directly used to compare signal strength across samples. This is particularly
problematic where the overall level of the bound protein varies across conditions,
as is the case for most of the histone modiﬁcations in this study. To address this
issue, we quantiﬁed the ChIP enrichments for each sample using a technique called
ChIP with reference exogenous genome (ChIP-Rx), which applies spike-in
Drosophila chromatin as internal control47. For each ChIP-seq proﬁle, we
calculated the ChIP-Rx ratio (denoted as Rx) as follows:
Rx ¼

s=s dmel
i=i dmel

where s is the percentage of reads mapped to human or mouse genome in the target
sample, s_dmel is the percentage of spike-in Drosophila genome in the sample, and
similarly i and i_dmel are deﬁned for the input sample. To compare the genomewide H3K27me3 distribution between H3K27M and H3WT cells, we normalized
the tracks using ChIP-Rx ratios as follows: for each sample, the read counts in the
genomic compartments (e.g., bins) were ﬁrst divide by the total number of reads,
then multiplied by ChIP-Rx ratio of the sample, and then multiplied by a
normalization factor (which is the same for all samples, set as 1010 here) to avoid
very small values.
We also normalized the ChIP-seq enrichments of target samples by their input
data. Let Si and Ni be the read counts in the i-th genomic compartment of the
sample and input, respectively, and TS and TN be the total read counts of the two
samples, the normalization on Si was done as follows:
Si norm ¼ log2

Si=TS
Ni=TN

To avoid 0 in denominator or logarithm, we added a pseudo count (denoted as c,
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here we set c = 1) during input-normalization, as follows:
ðSi þ cÞ=TS
Si norm ¼ log2
ðNi þ cÞ=TN
ChIP-sequencing coverage tracks were visualized using IGV 2.3 software48,49. To
call narrow peaks, we used “macs2 callpeak -t ${CHIP} -c ${INPUT} -f BAM -g hs -n
${NAME} -q 0.01–outdir ${OUTDIR}”. For broad histone marks, we call peaks
using “macs2 callpeak -t ${CHIP} -c ${INPUT} -f BAM–broad -g hs–broad-cutoff
0.1 -n ${NAME}–outdir ${OUTDIR}”.
Peak-calling was done using MACS250 version 2.1.1.
The SUZ12 peak-centered H3K27me2, H3K27me3 enrichment plots, and PMD
plot were generated using ngs.plot.r package51. The signal around SUZ12 peak
centers (+/−50 kb) was normalized by input and by ChIP-Rx ratio. The signal
around PMD regions was extended by 100 kb on each side. The following
command was used to generate the plots: “./ngs.plot.r -G hg19 -R bed -C {Conﬁg
ﬁle} -O {output ﬁle} -L {extend by number of bases}”. The conﬁg ﬁle contains the
names of H3K27me3/H3K27me2 and input BAM ﬁles and BED ﬁle name of
SUZ12 peaks for SUZ12-cenetered plot. For PMD plot, the conﬁg ﬁle contains the
BED ﬁle of PMD regions instead.
The aggregate plots of SUZ12, H3K27me2, and H3K27me3 for primary cell
lines were generated using deepTools v3.1.052. The signals were normalized by both
input and ChIP-Rx ratios as follows:
Si norm ¼ log2

ðRx  ðSi þ cÞÞ=TS
ðNi þ cÞ=TN

where Rx is the ChIP-Rx ratio, the rest variables have the same meanings as in the
input-normalization equation. The normalization was done using deepTools’
bamCompare, where the bin size and fragment length were set to 500 bp and 200
bp, respectively. After normalization, the signals were aggregated around (+/−50
kb) the centres of the top CGIs (for SUZ12) or TSS of repressed genes (for
H3K27me3) using deepTools’ computeMatrix and visualized by averaging the
score in bins equidistant from the mid-point (with NaN values discarded).
Heatmap plots for comparing H3K27me3, SUZ12, RING1B, and DNA
methylation were generated using ChAsE v.1.0.11 software53. The regions were
centered on CGIs, extending 5 kb, 10 kb, or 50 kb upstream and downstream.
We characterized the variations of H3K27me3 at CGIs in H3WT (or H3K27MKO) versus H3K27M cells by plotting the differential enrichment of H3K27me3
between the two conditions against the H3K27me3 enrichment in H3WT (or
H3K27M-KO) cells. Accordingly, the x and y axes are deﬁned as follows:




H3WT
H3K27M
X ¼ log2
; Y ¼ log2
INPUT
H3WT
where H3WT, H3K27M, and INPUT represent the processed read counts at CGIs
in the three types of samples, i.e., WT, K27M, and input ChIP-seq libraries. The
“processed read counts” here means the number of mapped reads at CGIs divided
by total read counts of the genome. Note that for H3WT and H3K27M, we also
multiplied the processed read counts by their ChIP-Rx ratios. We ﬁltered out the
CGIs, which overlap with the ENCODE DAC blacklisted regions54. To reduce
stochasticity in low coverage regions, we took the average of H3K27me3
enrichment in two available WT samples. Therefore, the x and y axes are modiﬁed
to:





1
H3WT 1
H3WT 2
X¼
log2
þ log2
;
2
INPUT 1
INPUT 2

Read counts from RNA-seq alignment were transformed (regularized log
transformation) using the rlog function from R package DESeq2. Differential
expressed (DE) genes between H3WT and H3K27M were deﬁned as genes with
log2FoldChange larger (Up genes) or smaller (Down genes) than 1 and with
adjusted p-value smaller than 0.05.
To make Decile plot of DE genes, ﬁrst we categorized the DE genes into ten
groups based on their expression levels in parental samples (i.e., before CRISPR
editing or overexpression). Then we counted the number of genes (including Up
genes and Down genes) in each category, and plotted the gene counts using
geom_bar in R Package ggplot2.
Gene set enrichment analysis (GSEA) was performed using the GSEA tool from
Broad Institute (https://software.broadinstitute.org/gsea/index.jsp)57,58.
Analysis of WGBS data. Raw reads were aligned to human genome build (UCSC
hg19) using BWA (version 0.6.1)59 after converting the reference genome to bisulﬁte
mode. Low-quality sequence at the 3′ ends were trimmed. And for the overlapping
paired-end reads, we clipped the 3′ end of one of them to avoid double counting. This
was done on both forward and reverse strand. After alignment, we ﬁltered reads that
were duplicate, or were poorly mapped (with more than 2% mismatches), or not
mapped at the expected distance based on the library insert size.
To call methylation of individual CpGs, Samtools59 (version 0.1.18) in mpileup
mode was applied. CpGs covered by less than ﬁve reads were removed. We also
discarded the CpGs that were overlapped with SNPs from dbSNPs (137) or were
located within the ENCODE DAC blacklisted regions or Duke excluded regions54.
To call partially methylated domains (PMDs), we used a window size of 10 kb
and slid the window on the measurements of methylation level at each CpG. For
each 10 kb window where the average methylation level of mCGs was less than 70%
(with each CpG covered by at least 5 MethylC-Seq reads), we extended the region
with increments of 10 kb until the average methylation level of the region was
greater than 70%. After that, we reported the regions with size larger than 1 Mb as
PMDs.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.

Code availability
Custom R scripts used to generate the top 1% bin scores, the plots of H3K27me3
variations, the correlation plots of K27M-K27me2 and WT-K27me3 and the Decile plots
are available upon request.

Data availability
The sequencing data reported in this paper are available for download through the
GenAP portal at https://datahub-jv6f4mbl.udes.genap.ca/. All other relevant data
supporting the key ﬁndings of this study are available within the article and
its Supplementary Information ﬁles or from the corresponding author upon reasonable
request. The source data underlying Figs. 1a, 1d, 2a, 2d, 3d-e, 5a and Supplementary
Figs 2, 4a, 7a, 8b-c, 8e-f, 9a-d, 10b-e, 11b-e, 13d, 16c-d, 17a-e, 18a-b, 19b and 20a-c are
provided as a Source Data ﬁle. A reporting summary for this Article is available as
a Supplementary Information ﬁle.
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Y ¼ log2ðH3K27MÞ  1=2  ðlog2ðH3WT1 Þ þ log2ðH3WT2 ÞÞ
The plot of H3K27me3 variations at promoters is similar to the one at CGIs. The
dots were colored based on the differential analysis of gene expression (see Analysis
of RNA-seq data for details). The H3K27me3 variations at promoters are
categorized into four groups: Gained in K27M, Absent, Lost in K27M, and
Retained. The categorization was based on H3K27me3 values in WT (x-axis) and
H3K27me3 difference (y-axis) as follows: for CGI/DNA methylation plot (Fig. 2g,
Supplementary Fig. 10g–h, 13a–c): Gained in K27M (BT245: y > 0; DIPGXIII: y >
2.6), Absent (BT245: y < 0, x < −3.75; DIPGXIII: y < 2.5, x < −5), Lost in K27M
(BT245: y < −4, x > −2.5; DIPGXIII: y < −2.5, x > −2.5), Retained (BT245: −3 < y
< 0, x > 1.25; DIPGXIII: y > −2, x > 0.5); for promoter/differential expression plot
(Fig. 4a): Gained in K27M (BT245: y > 0), Absent (BT245: y < 0, x < −2.5), Lost in
K27M (BT245: y < −4, x > −2.5), Retained (BT245: −3 < y < 0, x > 0).
To show the correlation between H3K27me2 in K27M and H3K27me3 in wildtype isogenic cells, we ﬁrst sorted the 1 kb non-overlapping bins based on the
H3K27me2 enrichment (after input normalization) in K27M cells, then grouped
the sorted bins into 1000 windows, and plot the mean values of ChIP enrichment
(WT-H3K27me3 and WT-H3K27me2) in the 1000 windows. We used the dashed
line to indicate the K27M-H3K27me2 enrichment per window. The procedure was
adapted from ref. 55.
Analysis of RNA-seq data. Raw reads were aligned to human genome build
(UCSC hg19) using STAR56 version 2.5.3a. For each sample, we counted the
mapped reads for each gene from annotation ﬁles in GTF format (downloaded
from UCSC Table Browser) using featureCounts program (version 1.5.3).
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